
Presented by

👋 Hey, let’s get into it. Remember the good ol’ days when $2.1 billion sounded like a lot of money? Isomorphic Labs raised that much six months ago and just went back for another $5 billion. Mind you, it’s still preclinical.
The Google DeepMind spinout will use the money to beef up its AI drug design engine and move its own and partnered drugs closer to human testing. Bloomberg reported a valuation of about $50 billion during the fundraising talks.
The next headline we’re looking for is a lot smaller. One patient, one dose.
📰 Headliners

💉 SELLAS Shares Jump 156% After Leukemia Vaccine Adds Nine Months to Median Survival
Nine extra months was the difference in median survival in SELLAS’s Phase 3 REGAL trial. Patients on its vaccine, galinpepimut-S, lived a median 24 months versus 14.7 months with the care their doctors picked. The study enrolled 126 people whose acute myeloid leukemia was in at least its second remission and who couldn’t get a donor stem cell transplant. The vaccine aims to help the immune system recognize lingering leukemia cells that make a protein called WT1. SELLAS plans to talk to the FDA about filing for approval. Its shares closed up about 156% on Tuesday.
💰 Pfizer Bets Up to $2.6 Billion on CAR-T Made Inside the Body
What if your T cells could skip the round trip? With conventional CAR-T, a patient’s cells get collected, sent off to be engineered, and infused back into the patient. Starna wants to do the engineering inside the body by delivering RNA instructions in tiny lipid particles. Pfizer is paying $330 million upfront for rights outside Greater China to three preclinical autoimmune programs. Starna could earn another $2.3 billion in milestones, plus royalties. If the approach works, patients could skip the wait for a batch of cells made just for them.
💊 FDA Approves Roche’s Pill for Advanced Breast Cancer
Roche’s new breast cancer pill just got the FDA’s green light. In the trial, patients with an ESR1 mutation went a median 10 months on Wilserdly plus everolimus before their cancer got worse or they died, versus 5.5 months on a different hormone therapy plus everolimus. The approval covers adults with advanced ER-positive, HER2-negative breast cancer with that mutation whose disease returned or progressed despite prior hormone therapy. Citi sees $14.5 billion in peak annual sales. The bigger prize is earlier-stage breast cancer, where Roche expects an FDA decision on use after surgery by November 30.
🎯 Lilly and Stipple Hunt for Cancer Targets With Up to $5.9 Billion in Milestones
Lilly has found yet another place to put its GLP-1 cash to work. This time it’s teaming up with Stipple Bio to solve an annoying problem in cancer drug design. The same protein can show up on a tumor and on healthy tissue. Stipple looks for a spot on that protein, called an epitope, that a drug could grab on the tumor while sparing healthy cells. Lilly is making an upfront payment and an equity investment, with both amounts undisclosed. Stipple could earn up to $5.9 billion in milestones across the programs, plus royalties.
🤝 Sponsored by Future Biotech Expo

🧬 Let’s Talk Biotech in Philly
Some of the best conversations at a biotech conference start with “So, what are you working on?”
On April 6–7, Future Biotech Expo 2027 brings scientists, biotech executives, pharma teams, and investors to Philadelphia to talk about what’s next in drug discovery, therapeutics, and biopharma.
If you’re looking for a research partner or curious how other teams are tackling the same problems you are, two days in Philly might beat another month of “let’s find a time to chat.”
BioNucleus will be there, and we’d love to meet some of the people on the other side of this newsletter. If you’re going, come find us and say hi!
⚡️ Quick Hits
🏛️ White House Pulls Heidi Overton’s FDA Nomination
The White House withdrew Heidi Overton’s nomination to lead the FDA ahead of a Senate committee vote yesterday.
🧠 Biogen’s Anti-Tau Drug Shows Its Strongest Two-Year Alzheimer’s Signal at the Lowest Dose
The lowest dose stood out in Biogen’s open-label Phase 2 Alzheimer’s extension, with 38% less decline at 96 weeks versus the original placebo group.
🛑 Merck Stops Three Phase 3 Blood Cancer Trials
Merck ended three Phase 3 nemtabrutinib trials after independent monitors questioned whether the blood cancer drug’s benefits outweighed its risks in one study.
💸 Biogen Bets Up to $411M on TrimTech’s Protein Degraders
Biogen took an option to license TrimTech’s experimental drugs for breaking down protein clumps in neurodegenerative diseases in a deal worth up to $411 million.
💊 Viagra-Like Alzheimer’s Pill Shows Promise as a Stand Alone Treatment
AriBio’s pill blocks the same enzyme as Viagra. It missed its overall Phase 3 goal, but decline was 31% slower in a prespecified subgroup taking it alone.
🫁 GSK Gets a Second Lung Cancer Approval From Its $10.6B Nuvalent Deal
Nelkarmi’s accelerated approval covers advanced ALK-positive lung cancer after alectinib as the sole prior ALK inhibitor or at least two ALK inhibitors plus platinum chemotherapy.
🇪🇺 RevMed’s Rasonque Wins EU Approval for Pancreatic Cancer
Following October’s favorable committee opinion, the European Commission approved Rasonque for adults with metastatic pancreatic adenocarcinoma who’ve already received at least one systemic therapy.
🩸 A New Blood Test Could Help Measure Alzheimer’s Progression
Researchers found the experimental blood test could pick up advanced tau tangles when they checked it against brain scans and autopsy findings.
🧐 Deep Dive

🪄 Summit’s Ivonescimab and the FDA’s Request for a Do-Over
Expelliarmus. Wingardium Leviosa. Ivonescimab. If you recognized the first two right away and had to stop and think about the third…we get it. That last one is Summit’s lung cancer drug. On Tuesday, we covered the FDA’s rejection and the survival result Summit pointed to. Well, the FDA has since shared its note with the rest of the class, and there’s more in there than a missed survival result.
First, the part that looked good. In the Phase 3 HARMONi trial, patients with advanced EGFR-mutated lung cancer whose disease had progressed after EGFR-targeted treatment went a median 6.8 months before their cancer got worse or they died on ivonescimab plus chemo. On chemo alone, it was 4.4 months. Overall survival came in at 16.8 versus 14 months, a difference that fell short of statistical significance.
Here’s where the FDA pulled out a calculator. China accounted for about 60% of the patients and started enrolling them in 2022. North America and Europe didn’t start until May 2023. By the cutoff, 257 of the 275 cases of progression or death in the main analysis came from China. That’s 93%. With only 18 events from everywhere else, the FDA said the results couldn’t establish whether U.S. patients would see the same benefit.
The agency also had to ask whether those extra months without progression were worth the added risks, including serious immune-related side effects. Its answer was to recommend a new trial across regions that shows enough benefit to justify those risks. That means signing up patients and collecting a fresh set of data.
Summit announced another Phase 3 trial on Wednesday, this time against Imfinzi after chemoradiation in inoperable stage III lung cancer. That’s another shot for the drug. The application we talked about Tuesday still needs its own evidence.
🔢 Key Figure
3.5 Million
That’s how many U.S. surgeries a year fall into categories the FDA just cleared Medtronic’s Hugo surgical robot to assist with, the company estimates. Those include gallbladder removals and hernia repairs. If you run a hospital, that’s more chances to get your money’s worth out of the same machine.
🌎 Community Vibes
Here’s what biotech Redditors are talking about:
🔥 Fire Kills Cancer Cells in the Lab. Funding, Please!
Someone spotted what looked like a paid LinkedIn ad celebrating a study that killed cancer cells in a dish. One commenter suggested a flamethrower will do the same. Another said they regularly kill cancer cells while trying very hard to keep them alive. Obviously, the hard part is sparing the healthy cells. One could probably kill the cancer cells by pouring them on the lab floor then jumping up and down on them. Makes for an awkward clinical trial, though.
💡 What Biotech Ideas Are Dealmakers and VCs Overlooking?
A Redditor asked what pharma dealmakers and VCs are sleeping on. Ideas included drugs that switch on only after multiple biological signals, chemical messages from gut microbes, and CAR-T. That last one got people talking about how hard it is to scale. Weird…nobody said biotech newsletters. Explains the lack of VC funding. What biotech technology deserves more attention over the next five years, and why? Hit reply and we’ll share a few ideas in the next issue.
🧬 BioBits
🤖 Magnetic Microbots Help Clot-Busting Drugs Reach Their Target
Tumbling magnetic microbots moved medicine toward a blockage, helping it dissolve clots six times faster in a lab model that used pig blood.
💉 Hims & Hers Launches Peptides+ With Five Compounded Treatments
Hims & Hers launched Peptides+ with five compounded treatments that lack FDA approval, and the company acknowledges open questions about how well they work.
🌍 WHO and UNEP Flag Hormone-Disrupting Exposures Before Birth
The agencies’ first update since 2012 highlights prenatal exposure to hormone-disrupting chemicals and how little testing accounts for the mixtures people actually encounter.
🚀 Startup Spotlight
🧬 Ansa Raises $71.5 Million to Make DNA Ship Dates More Predictable
Everyone’s ready for Tuesday’s experiment, except the DNA order. Ansa Biotechnologies raised a $71.5 million Series C led by Blue Water Life Science Advisors to expand its capacity to make and sell synthetic DNA. It guarantees ship dates for eligible orders, which sounds like a small perk until three people have blocked off a day for work that depends on one shipment. The round brings Ansa’s total funding to $211 million. What labs are buying, along with the DNA, is a date they can put on the calendar.
🗓️ This Day in History
🦣 November 19, 2008: DNA From 20,000 Year Old Woolly Mammoth Hair Gets Sequenced
A bad hair day for a woolly mammoth turned out to be a pretty good day for genomics. On November 19, 2008, news broke that researchers had recovered much of the mammoth’s nuclear genome from hair preserved in Siberian permafrost. One specimen was about 20,000 years old. The hair protected DNA inside, and the team could wash away much of the microbial contamination on the outside. Across several specimens, they identified 3.3 billion bases of mammoth DNA. Sometimes the biggest break comes from what you put in the sequencer.
🤔 Final Thoughts
Thinking back to the opening story, I used to think you’d need at least a Phase 1 trial to raise $5 billion in biotech. Turns out you can get there a little earlier if you’re a Google DeepMind spinout with “AI drug discovery” in the company description.
You know…BioNucleus and Isomorphic have a lot in common. We’re both in biotech, and neither of us has started a Phase 1 trial. I just need to add “AI drug discovery” to our pitch deck. By my calculations, that should put our valuation at around $2 billion, give or take $2 billion. 🙃
That’s all for today. See you Tuesday for the next issue.
✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.
📣 Interested in Sponsoring BioNucleus?
Put your brand in front of scientists, founders, investors, operators, and other professionals across biotech and pharma.
BioNucleus Briefing has 3,000+ combined subscriptions across our email and LinkedIn newsletters, with one exclusive sponsor per issue.
Think your company could be a fit? Learn more about our audience and get in touch about an upcoming campaign.
If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.
Was this email forwarded to you? Sign up here 👇
Follow us on social and stay one step ahead